TELA Bio, Inc. (TELA) |
| 0.8173 -0.03 (-3.51%) 07-13 16:00 |
| Open: | 0.8969 |
| High: | 0.8969 |
| Low: | 0.8116 |
| Volume: | 86,957 |
| Market Cap: | 37(M) |
| PE Ratio: | -1.05 |
| Exchange: | NASDAQ |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 1.00 |
| Resistance 1: | 0.87 |
| Pivot price: | 0.78 |
| Support 1: | 0.67 |
| Support 2: | 0.56 |
| 52w High: | 2.186 |
| 52w Low: | 0.501 |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| EPS | -0.780 |
| Book Value | -0.120 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.222 |
| Profit Margin (%) | -49.30 |
| Operating Margin (%) | -55.23 |
| Return on Assets (ttm) | -28.7 |
| Return on Equity (ttm) | -616.6 |
Thu, 02 Jul 2026
TELA Bio Inc. (TELA) Shows Modest Uptick as Stock Tests Key Resistance - Volume Weighted Price - DonanımHaber
Thu, 25 Jun 2026
TELA Forecast — Price Target — Prediction for 2027 - TradingView
Fri, 19 Jun 2026
TELA Bio Inc (TELA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fri, 15 May 2026
Earnings Release: Here's Why Analysts Cut Their TELA Bio, Inc. (NASDAQ:TELA) Price Target To US$2.25 - Yahoo Finance
Wed, 13 May 2026
Becton Hernia Mesh Antitrust Case Survives Dismissal - Law360
Tue, 12 May 2026
TELA Bio Reports First Quarter 2026 Financial Results - GlobeNewswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |